Lilly's Lebrikizumab Significantly Improved Skin Clearance and Itch in People with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials
INDIANAPOLIS, Aug. 16, 2021 /PRNewswire/ -- Lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), as measured by EASI, in Eli... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 16, 2021 Category: Pharmaceuticals Source Type: clinical trials
Effect of a Topical Spray on Itch Relief in Moderate-to-severe Childhood Eczema
Condition: Eczema Intervention: Drug: Atoderm SOS spray Aerosol 200ml Sponsor: Prof. HON Kam Lun Ellis Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 2, 2021 Category: Research Source Type: clinical trials
